Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Kurt, R. A.
Right arrow Articles by Akporiaye, E. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kurt, R. A.
Right arrow Articles by Akporiaye, E. T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

International Immunology, Vol. 12, No. 5, 639-646, May 2000
© 2000 Japanese Society for Immunology

TCR Vß usage and clonality of T cells isolated from progressing and rejected tumor sites before and after in vitro culture

Robert A. Kurt, Julie A. Park1, Samuel F. Schluter1, John J. Marchalonis1 and Emmanuel T. Akporiaye1

Earle A. Chiles Cancer Research Institute, 4805 NE Glisan Suite 5F40, Portland, OR 97213, USA
1 Department of Microbiology and Immunology, University of Arizona, Tucson, AZ 85724, USA

Correspondence to: R. A. Kurt

A gelatin sponge model of concomitant tumor immunity was employed in order to examine the clonality of T cells associated with progressing and rejected tumor sites. Here we show that freshly isolated T cells bearing TCR Vß1, CDR3 RPGTGN, Jß1.1 and TCR Vß8, CDR3 GD, Jß1.6 predominated progressing and rejected tumor sites. Despite the similarity in T cell populations, the T cells from rejected tumor sites were capable of killing the autologous tumor cells, whereas T cells from progressing tumor sites were not able to do so. The differing cytolytic ability could not be attributed to a difference in TCR {zeta} chain protein expression levels between both T cell populations. After a 5 day mixed lymphocyte tumor culture the T cells from the progressing tumor site were capable of killing autologous tumor cells, which suggested changes took place within the cell population during in vitro culture. Further TCR analysis revealed T cells bearing TCR Vß1, CDR3 RPGTGN, Jß1.1 and TCR Vß8, CDR3 GD, Jß1.6 were not expanded following the in vitro culture. These data suggest that the lack of cytotoxicity of freshly isolated tumor-infiltrating lymphocytes (TIL) was not due to abnormal TCR {zeta} chain expression or major differences in the TCR Vß usage. Additionally, the gain of TIL effector function did not correlate with an expansion of the TCR bearing T cells found to predominate the in vivo response. These data suggest that the predominant TCR Vß used by lymphocytes infiltrating regressing or rejected tumors may not represent the tumor reactive T cells that grow in culture or respond to the autologous tumor in vitro.

Keywords: T lymphocyte, TCR {zeta}, tumor immunity, tumor-infiltrating lymphocyte, tumor-rejecting lymphocytes

Transmitting editor: M. M. Davis


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.